BS01

BS01 is a recombinant adeno-associated virus (AAV)-based gene therapy developed for the treatment of retinitis pigmentosa. It expresses an enhanced light-sensitive channelrhodopsin gene, which encodes optogenetic proteins that activate the optic nerve directly, bypassing damaged retinal photoreceptors. The therapy aims to restore vision by enabling light perception and object recognition in patients with advanced retinal degeneration. Delivered as a one-time intravitreal injection, BS01 has shown promising results in early clinical trials, including significant improvements in light sensitivity and visual acuity without serious safety concerns. The therapy is paired with a device that sends signals to the treated ganglion cells to further enhance visual function[1][2][3][5][6].

Other names

prebiotic BS-01